Patents Assigned to GRÜNENTHAL GMBH
  • Publication number: 20210163491
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Grünenthal GmbH
    Inventors: Florian JAKOB, Jo ALEN, Simon LUCAS, Tobias CRAAN, Ingo KONETZKI, Achim KLESS, Stefan SCHUNK, Paul RATCLIFFE, Sebastian WACHTEN, Simon CRUWYS
  • Patent number: 11013701
    Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 25, 2021
    Assignee: Grünenthal GmbH
    Inventors: Marc Schiller, Carlos van Hemelrijck, Stefanie Straub, Eva Wulsten, Ulrike Bertram, Ulrich Reinhold
  • Patent number: 11007156
    Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: May 18, 2021
    Assignee: GRUENENTHAL GMBH
    Inventors: Johannes Bartholomaeus, Iris Ziegler
  • Publication number: 20210130282
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 6, 2021
    Applicant: GRÜNENTHAL GMBH
    Inventors: WOLFGANG HELL, OSWALD ZIMMER, HELMUT HEINRICH BUSCHMANN, JOERG HOLENZ, STEFAN GLADOW
  • Patent number: 10981918
    Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 20, 2021
    Assignee: GRÜNENTHAL GMBH
    Inventors: Florian Jakob, Jo Alen, Simon Lucas, Tobias Craan, Ingo Konetzki, Achim Kless, Stefan Schunk, Paul Ratcliffe, Sebastian Wachten, Simon Cruwys
  • Publication number: 20210046009
    Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 18, 2021
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, SEBASTIAN SCHWIER, ULRIKE BERTRAM
  • Patent number: 10912763
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: February 9, 2021
    Assignee: Grünenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • Publication number: 20210032256
    Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: September 2, 2020
    Publication date: February 4, 2021
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Patent number: 10898452
    Abstract: The invention relates to an an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof; wherein the concentration of Tapentadol is greater than 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; wherein the composition comprises a buffer system; and wherein the pH value of the composition is within the range of from greater than 3.0 to less than 6.7. The invention also relates to a kit comprising the composition according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in adult patients.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: January 26, 2021
    Assignee: GRUENENTHAL GMBH
    Inventors: Angelika Ellermann, Ulrich Reinhold, Ulrike Bertram
  • Publication number: 20200399280
    Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
  • Publication number: 20200399252
    Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, lngo KONETZKI
  • Publication number: 20200399255
    Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Publication number: 20200399226
    Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 24, 2020
    Applicant: Grünenthal GmbH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • Publication number: 20200397704
    Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Patent number: 10864164
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 15, 2020
    Assignee: Grünenthal GmbH
    Inventors: Sebastian Schwier, Marcel Haupts, Lutz Barnscheid, Jana Pätz
  • Publication number: 20200385334
    Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 10, 2020
    Applicant: Grünenthal GmbH
    Inventors: Andreas Fischer, Helmut Buschmann, Michael Gruss, Dagmar Lischke
  • Publication number: 20200375905
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
  • Patent number: 10842750
    Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 24, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Sebastian Schwier, Ulrike Bertram
  • Patent number: 10829480
    Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 10, 2020
    Assignee: GRUENENTHAL GMBH
    Inventors: Sven Kuehnert, Rene Michael Koenigs, Achim Kless, Anita Wegert, Paul Ratcliffe, Ruth Jostock, Thomas Koch, Klaus Linz, Wolfgang Schroeder, Klaus Schiene, Ingo Konetzki
  • Publication number: 20200338069
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than. 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID